Fibrilación Auricular (Adyuvante Investigacional)

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?

Not FDA-cleared for atrial fibrillation. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for AF is highly investigational.

¿Qué evidencia existe?

Tier C (highly investigational). Only anecdotal case reports exist; there are no randomized controlled trials. Evidence-based AF care per ACC/AHA/HRS 2023 guidelines requires CHA2DS2-VASc-based stroke-risk stratification, anticoagulation (DOACs preferred for most patients), and rate or rhythm control with proven medications, cardioversion, or catheter ablation. Most AF patients need lifelong anticoagulation — which is an absolute contraindication to leech therapy.

Riesgos principales

• Stroke if anticoagulation is interrupted to allow leech therapy (this is the dominant risk)
• Bleeding from bite sites for 6 to 24 hours after detachment
• Bruising over the chest wall for 5 to 10 days
• Light-headedness, palpitations, or worsening AF symptoms during the session
• Local skin infection or, rarely, Aeromonas infection
• Allergic reaction to leech saliva (uncommon)
• Delay or replacement of guideline-directed therapy with risk of stroke, heart failure, or sudden cardiac event

Quién no debería considerar esto

• Patients on any anticoagulant (warfarin, DOACs, heparin) — anticoagulation in AF should NOT be paused for complementary therapy
• Patients with CHA2DS2-VASc score of 2 or higher (men) / 3 or higher (women) who require anticoagulation
• Patients within 3 months of cardioversion or ablation
• Patients with decompensated heart failure, recent MI, or unstable angina
• Patients with severe anemia, active infection, hemophilia, or immunosuppression
• Pregnant patients

Qué preguntar a su clínico

• What is my CHA2DS2-VASc score, and do I require anticoagulation?
• Is my AF rate-controlled or rhythm-controlled, and is the current strategy appropriate?
• Am I a candidate for catheter ablation or left atrial appendage closure?
• What is the cardiology team's opinion on adjunctive complementary therapy in my specific case?
• If I pursue this, will my anticoagulation be paused, and what is the stroke-risk implication?
• What is the practitioner's experience and Aeromonas-prevention plan?
• How will I be monitored (ECG, symptom diary) during the course?

Cuándo buscar atención urgente

• Sudden weakness on one side, slurred speech, facial droop, or vision loss (possible stroke — call 911)
• Chest pain, pressure, or shortness of breath (possible MI or pulmonary embolism — call 911)
• Rapid heart rate over 130 with symptoms (chest pain, dyspnea, near-fainting)
• Loss of consciousness or near-loss of consciousness
• Bleeding from a bite site lasting more than 24 to 48 hours
• Fever above 38.0 C / 100.4 F, spreading redness, or pus
• Hives, throat tightness, or breathing difficulty